Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib

Nina Prokoph, Jamie D. Matthews, Ricky M. Trigg, Ivonne A. Montes-Mojarro, G. A.Amos Burke, Falko Fend, Olaf Merkel, Lukas Kenner, Birgit Geoerger, Robert Johnston, Matthew J. Murray, Charlotte Riguad, Laurence Brugières, Suzanne D. Turner*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science